Breaking Research News from ASCO

› Forums › General Melanoma Community › Breaking Research News from ASCO

  • Post
    • June 2, 2013 at 5:38 pm
    mrf
    Keymaster
      A number of important melanoma research updates have emerged from the American Society of Clinical Oncology (ASCO) annual meeting, including a report on Sunday, June 2 about the combination of ipilimumab and nivolumab. Both drugs are designed to engage the immune system in fighting melanoma. In the study, the combined drugs helped shrink tumors in 38% of patients overall. One arm of the study generated a 52% response rate in patients. The study has been published online in the New England Journal of Medicine.

      A number of important melanoma research updates have emerged from the American Society of Clinical Oncology (ASCO) annual meeting, including a report on Sunday, June 2 about the combination of ipilimumab and nivolumab. Both drugs are designed to engage the immune system in fighting melanoma. In the study, the combined drugs helped shrink tumors in 38% of patients overall. One arm of the study generated a 52% response rate in patients. The study has been published online in the New England Journal of Medicine.

    Viewing 2 reply threads
    • Replies
    Viewing 2 reply threads
    • You must be logged in to reply to this topic.
    About the MRF Patient Forum

    The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

    The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

    Popular Topics